Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Department of Radiation Oncology, University Hospital of Zurich, Switzerland and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Rhinology. 2023 Dec 1;61(6):508-518. doi: 10.4193/Rhin23.204.
This meta-analysis aims to investigate the outcome of sinonasal adenoid cystic carcinoma (snAdCC). We followed PRISMA guidelines and included studies reporting 5-year overall survival (OS) rates for snAdCC. Eligible studies were identified through a literature search and assessed using JBI critical appraisal checklist. A total of 17 studies were included comprising 2259 patients (mean age: 58.1 years, 52.7% female, 47.3% male). The meta-analysis demonstrated that the 5-year OS, 10-year OS, and 5-year disease-free survival (DFS) were 68%, 40%, and 47.2%, respectively. Descriptive statistics on study level showed high rates of locally advanced tumor stages at diagnosis: 23% cT3, 53% cT4, 3.4% N+, and 4.2% M+. 29.7% of the tumors were in the nasal cavity, 67.6% in the paranasal sinuses. The maxillary, ethmoid, sphenoid, and frontal sinus were affected in 50.9%, 7.2%, 4%, and 0.5%, of cases. A combination of surgery and radiotherapy was used in 45.4% of the patients and 19.3% of patients received surgery only. In conclusion, these findings emphasize the significance of thorough surveillance for individuals with snAdCC to identify any potential recurrence or progression of the disease.
本荟萃分析旨在探讨鼻腔鼻窦腺样囊性癌（snAdCC）的预后。我们遵循 PRISMA 指南，纳入了报告 snAdCC 5 年总生存率（OS）的研究。通过文献检索确定合格的研究，并使用 JBI 批判性评估清单进行评估。共纳入了 17 项研究，包含 2259 名患者（平均年龄：58.1 岁，女性占 52.7%，男性占 47.3%）。荟萃分析结果显示，5 年 OS、10 年 OS 和 5 年无病生存率（DFS）分别为 68%、40%和 47.2%。研究水平的描述性统计显示，诊断时局部晚期肿瘤分期比例较高：23% cT3、53% cT4、3.4% N+和 4.2% M+。29.7%的肿瘤位于鼻腔，67.6%位于副鼻窦。上颌窦、筛窦、蝶窦和额窦受累分别占 50.9%、7.2%、4%和 0.5%。45.4%的患者接受手术联合放疗，19.3%的患者仅接受手术治疗。总之，这些发现强调了对 snAdCC 患者进行彻底监测的重要性，以识别疾病的任何潜在复发或进展。
